Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw some unusual options trading on Wednesday. Traders bought 29,275 call options on the company. This represents an increase of approximately 43% compared to the average volume of 20,478 call options.
Recursion Pharmaceuticals Stock Up 4.3%
RXRX traded up $0.23 on Wednesday, hitting $5.59. 34,337,002 shares of the company were exchanged, compared to its average volume of 16,395,603. Recursion Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a market cap of $2.27 billion, a price-to-earnings ratio of -3.16 and a beta of 0.91. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $4.82 and a two-hundred day moving average price of $6.09.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The company had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. The company's revenue for the quarter was up 7.2% compared to the same quarter last year. On average, equities analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the business. AlphaQuest LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $36,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after purchasing an additional 2,026 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after purchasing an additional 2,387 shares during the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $54,000. 89.06% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of brokerages have recently weighed in on RXRX. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price objective on the stock. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $7.00.
Get Our Latest Report on Recursion Pharmaceuticals
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.